Trevena Announces Preliminary TRV045 Data from Two Proof-of-

Trevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target Engagement

Trevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target Engagement

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Michigan , United States , Daniel Clauw , Carrie Bourdow , Barry Shin , Mark Demitrack , Bob Yoder , Company Annual Report On Form , Company Contact , Trevenatrevena Inc , Exchange Commission , Trevena Inc , Webcast Informationthe Company , Nasdaq , National Institutes Of Health , Business Officertrevena Inc , Dan Ferrymanaging Directorlifesci Advisors , Company To Hold Conference Call On , University Of Michigan , Statistically Significant Analgesic Effect , Capsaicin Induced Model , Neuropathic Pain , Target Engagement , Provided Statistically Significant Evidence , Full Safety , Tolerability Data Expected , Hold Conference Call , Von Frey , Painful Surface Area , Overall Treatment Difference , Allodynic Area , Investigational New Drug Application , Chief Executive Officer , Senior Vice President , Chief Medical Officer , Chief Financial , Call Details , National Institutes , Nobel Prize , Private Securities Litigation Reform Act , Risk Factors , Annual Report , Quarterly Reports , Ferrymanaging Directorlifesci Advisors , Chief Business Officertrevena ,